Zevra Therapeutics' Profit Streak Continues Tomorrow, But Revenue Growth Remains the Question
Zevra has established a consistent pattern of exceeding expectations over the past four quarters, with every report delivering a positive surprise. The most recent quarter (Q1 2026) saw reported EPS of $0.18 versus $0.06 estimated, a +200% beat. This followed an extraordinary Q4 2025 result of $1.16 versus $0.04 estimated (+2,800% surprise), though that figure was heavily influenced by the SDX asset sale gain.
Stripping out the Q4 anomaly, the trend remains constructive: Q3 2025 delivered -$0.01 versus -$0.04 estimated (+75% beat), and Q2 2025 posted -$0.06 versus -$0.09 estimated (+33% beat). The progression from losses to profitability—and the magnitude of beats tightening as estimates catch up—suggests analysts have been consistently behind the curve on MIPLYFFA's commercial acceleration.
The +233% year-over-year growth estimate for Q2 2026 reflects this inflection, but the sequential step-down from Q1's $0.18 to the $0.08 consensus implies either conservative positioning by analysts or genuine headwinds from inventory normalization and slower enrollment growth. Given the four-quarter beat streak, the bar is set for another upside surprise, but the magnitude may compress as the business matures and estimates recalibrate.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Jun 2025 | $-0.09 | $-0.06 | +33.33% | Beat |
| Sep 2025 | $-0.04 | $-0.01 | +75.00% | Beat |
| Dec 2025 | $0.04 | $1.16 | +2,800.00% | Beat |
| Mar 2026 | $0.06 | $0.18 | +200.00% | Beat |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Zevra typically reports after market close, meaning Day 0 captures anticipatory trading before results drop, while Day +1 reflects the market's first full reaction session.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-06 | +$0.64 (+6.03%) | $0.73 (6.88%) | -$0.25 (-2.22%) | $0.99 (8.80%) |
| 2026-03-09 | +$0.14 (+1.56%) | $0.39 (4.34%) | +$1.94 (+21.27%) | $0.89 (9.76%) |
| 2025-11-05 | +$0.28 (+2.86%) | $0.93 (9.50%) | -$0.98 (-9.73%) | $1.04 (10.33%) |
| 2025-08-12 | +$0.06 (+0.51%) | $0.40 (3.42%) | -$2.33 (-19.81%) | $1.57 (13.35%) |
| 2025-05-13 | +$0.12 (+1.55%) | $0.40 (5.16%) | +$0.27 (+3.43%) | $0.73 (9.28%) |
| 2025-03-11 | +$0.07 (+0.88%) | $0.34 (4.25%) | -$0.15 (-1.86%) | $0.98 (12.14%) |
| 2024-11-12 | -$0.39 (-4.35%) | $0.74 (8.22%) | +$0.09 (+1.05%) | $0.96 (11.20%) |
| 2024-08-13 | -$0.03 (-0.44%) | $0.37 (5.43%) | +$0.21 (+3.10%) | $0.61 (9.00%) |
| Avg Abs Move | 2.27% | 5.90% | 7.81% | 10.48% |
Historical price action shows significant volatility around earnings, with an average absolute Day +1 move of 7.81% and a range of 10.48%. The most dramatic recent move came after Q4 2025 results (March 9, 2026), when the stock surged +21.27% on the day following the +2,800% EPS beat driven by the asset sale. Conversely, Q3 2025 (August 12, 2025) saw a -19.81% decline despite a +75% EPS beat, suggesting the market focused on forward guidance or underlying trends rather than the headline number.
More recent action has been muted: Q1 2026 results triggered only a -2.22% Day +1 move despite the +200% beat, indicating either profit-taking after the prior quarter's surge or concerns about the sequential revenue outlook. The 2.27% average Day 0 move and 5.90% Day 0 range suggest limited pre-announcement speculation, with the bulk of volatility concentrated in the post-results session. Investors should prepare for a potential double-digit percentage swing based on how revenue trends and guidance compare to the Street's recalibrated expectations.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 17) |
| Expected Move | $0.43 (4.04%) |
| Expected Range | $10.10 to $10.95 |
| Implied Volatility | 86.36% |
The options market is pricing a 4.04% expected move through the August 21 expiration (17 days out, encompassing the August 5 earnings release). This is significantly below the 7.81% average historical Day +1 move, suggesting options traders may be underpricing potential volatility—or anticipating a more subdued reaction as the MIPLYFFA story matures and estimates converge with reality. The 86.36% average implied volatility reflects elevated uncertainty, but the directional magnitude implied by the straddle appears conservative relative to the stock's recent earnings history.
Part 3: What Analysts Are Saying
Analyst sentiment on Zevra is overwhelmingly bullish, with 9 of 10 analysts rating the stock a Strong Buy and the remaining analyst at Hold. The 4.80 average recommendation (on a 5-point scale where 5 = Strong Buy) reflects near-unanimous conviction in the MIPLYFFA commercial opportunity and pipeline optionality. The consensus has remained unchanged over the past month, indicating stable conviction heading into the Q2 report.
The $25.00 mean price target implies +138% upside from the current $10.52 price, with a range of $20.00 to $35.00. The wide target spread reflects differing assumptions on MIPLYFFA's peak sales potential, European approval timing, and Celiprolol's probability of success. The bullish case (represented by the $35.00 high target) likely assumes accelerated enrollment, successful EMA approval, and sustained operating leverage as the company scales. The $20.00 low target still implies +90% upside, suggesting even the most conservative analyst sees significant value at current levels.
The unchanged sentiment trend despite the stock's recent weakness (trading below the 20-day, 50-day moving averages) indicates analysts view any pullback as a buying opportunity rather than a fundamental reassessment. With coverage at 69% of lives, orphan exclusivity through 2031, and a debt-free balance sheet, the structural bull case remains intact—but execution on enrollment growth and European expansion will be critical to justifying the lofty targets.
Part 4: Technical Picture
The Barchart Technical Opinion currently registers a Buy signal at 24%, up from 8% last week but down sharply from 100% last month, indicating recent deterioration in momentum despite a short-term bounce. The stock is navigating a challenging technical setup after pulling back from recent highs.
Timeframe Analysis:
- Short-term (Hold): Neutral reading suggests near-term momentum has stalled after the recent decline, with the stock consolidating ahead of earnings
- Medium-term (50% Buy): Moderate buy signal indicates the intermediate trend remains constructive despite recent weakness, reflecting the longer-term MIPLYFFA growth narrative
- Long-term (50% Buy): Moderate buy signal shows the broader uptrend from the commercial inflection remains intact, though not without volatility
Trend Characteristics: The Soft Weakening characterization reflects a loss of upside momentum without a full trend reversal—the stock is digesting gains rather than breaking down, but lacks conviction heading into the catalyst.
ZVRA is trading at $10.52, positioned above the 5-day ($9.90), 10-day ($10.31), and 200-day ($10.10) moving averages, but below the 20-day ($11.72), 50-day ($12.19), and 100-day ($11.12) averages. This mixed picture—short-term support holding but intermediate resistance overhead—suggests the stock has found a floor near $10 but needs a catalyst to reclaim the $11-$12 zone.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $9.90 | 50-Day MA | $12.19 |
| 10-Day MA | $10.31 | 100-Day MA | $11.12 |
| 20-Day MA | $11.72 | 200-Day MA | $10.10 |
Key resistance sits at the 20-day moving average ($11.72), which has capped recent rallies, while support clusters around the 200-day average ($10.10) and the recent $9.90 low. The 4.04% options expected move implies a range of $10.10 to $10.95, bracketing current technical levels. The overall setup is cautiously constructive—the stock has stabilized after recent weakness and holds above long-term support, but lacks the momentum to break higher without a strong earnings beat and forward guidance. Given the historical 7.81% average post-earnings move and the stock's tendency for double-digit swings, a decisive break above $11.72 on strong results could trigger a run toward the $12-$13 zone, while a miss or disappointing guidance could retest the $9-$10 support area. The technical picture favors waiting for the earnings reaction rather than positioning aggressively beforehand.